Clinical trials
Macular Degeneration clinical trials
Below are recruiting macular degeneration clinical trials, each written for real people, not researchers. We’re tracking 164 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03921931Recruiting
Test retinal responses to light in healthy eyes or eye disease
This is a small pilot study that measures how parts of the retina change before and after light stimulation. It may help researchers understand eye function in people with normal vision or specific eye conditions like glaucoma or dry age-related macular degeneration (AMD).
Vienna, State of ViennaAges 18 years+ - NCT07085533Recruiting
A Study of Inherited Retinal Diseases
This study is looking at how inherited retinal diseases affect color vision over time. It may help researchers understand these conditions better and is a good fit for people with a known diagnosis who can describe what they see.
WuhanAges Any age - NCT07053358RecruitingEarly Phase 1
Gene therapy for wet AMD
This trial tests a new gene therapy (LX111) for people with wet age-related macular degeneration (AMD) who have already been helped by standard anti-VEGF injections. The goal is to see if one dose of LX111 can reduce the need for frequent eye injections.
ShanghaiAges 50 years+ - NCT07029945RecruitingPhase 1/Phase 2
Oral BRX011 for advanced dry age-related macular degeneration
This study tests an oral medication called BRX011 taken once daily for geographic atrophy, a progressive form of advanced dry age-related macular degeneration. The goal is to see if it is safe and can help slow vision loss.
Gilbert, ArizonaAges 55 years+ - NCT07015034Recruiting
Preventing vision loss in older adults with chronic conditions
This study tests a model to help general practitioners find older patients who may be at risk of vision loss. It aims to spot problems early so treatment can start sooner.
Copenhagen, Capital RegionAges 70 years+ - NCT07005323Recruiting
Treatment for age-related macular degeneration that has not improved with standard therapy
This trial tests a new treatment for people with a specific type of age-related macular degeneration (AMD) that has not improved after standard anti-VEGF injections. The goal is to see if it can stop vision loss and reduce retinal damage.
Nagoya, Aichi-kenAges 18–85 - NCT07004361Recruiting
Ethics of gene therapy for wet AMD
This study explores the ethical questions around using gene therapy for wet age-related macular degeneration (AMD). It is not a treatment trial, but a discussion study for patients whose doctors might consider gene therapy as an option.
Nantes, NantesAges 18 years+ - NCT06990269RecruitingPhase 2
Study of ADX-038 for geographic atrophy in dry AMD
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
Gilbert, ArizonaAges 60 years+ - NCT06943599Recruiting
Improving Eye Care After Screening
This study looks at better ways to help people get follow-up eye care after a screening. If you were in the VIEW II study and were referred to an eye hospital, this trial may offer strategies to support you in getting that care.
San Francisco, CaliforniaAges 60 years+ - NCT06906003Recruiting
Vision rehab and depression in age-related macular degeneration
This trial tests whether visual rehabilitation can help improve both vision and mood in people with advanced dry age-related macular degeneration. It aims to understand the link between vision loss and depression.
Rome, ItalyAges 55 years+ - NCT06859515Recruiting
Long-term follow-up for wet AMD treatment
This study checks on the long-term safety and effects of a one-time treatment (EXG102-031) for wet age-related macular degeneration. It is only for people who already received that treatment in a previous study.
BeijingAges 50 years+ - NCT06847542RecruitingPhase 3
Study of a refillable eye implant for wet AMD
This trial tests a refillable eye implant (PDS) that slowly releases medication to treat wet age-related macular degeneration (nAMD). It aims to see if replacing the implant every 36 weeks works as well as regular eye injections.
InnsbruckAges 50 years+ - NCT06843499Recruiting
AI eye screening for AMD and diabetic retinopathy
This trial tests an AI program called VeriSee that helps doctors check for eye problems like age-related macular degeneration (AMD) and diabetic retinopathy (DR). It compares the AI's accuracy and costs to standard care in regular eye clinics.
Taipei, TaiwanAges 20 years+ - NCT06737354Enrolling by invitationPhase 1
Study of IVB103 injection for wet age-related macular degeneration
This trial tests a new treatment called IVB103 for people with wet age-related macular degeneration (AMD). It aims to see if the injection is safe and effective for those who have already had anti-VEGF therapy. You may qualify if you have active disease and have had at least two prior anti-VEGF treatments.
Chengdu, SichuanAges 50 years+ - NCT06682455Enrolling by invitation
Predicting AMD progression with advanced scans and AI
This study is looking at people with intermediate AMD who previously took part in the PINNACLE study. It will use advanced eye scans and machine learning to learn more about how AMD progresses and how to predict it.
ViennaAges Any age - NCT06659445RecruitingPhase 2
Study of ONL1204 for geographic atrophy in dry AMD
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
Gilbert, ArizonaAges 55 years+ - NCT06619405Recruiting
Eye Function Test for Age-Related Macular Degeneration
This study tests a quick, noninvasive eye test that measures how well you see in the dark, which can be an early sign of dry AMD. Researchers want to see if the test relates to everyday tasks like reading or driving at night.
Durham, North CarolinaAges 50–89 - NCT06604104Recruiting
Visual Frailty Study in Older Adults with AMD
This study looks at something called 'visual frailty' in older adults with advanced age-related macular degeneration (AMD). It aims to develop a tool to better understand how vision loss affects daily life and overall health in people aged 60 and over.
Edinburgh, ScotlandAges 60 years+ - NCT06593405RecruitingEarly Phase 1
Occupational therapy for eye disease medication management
This trial tests whether occupational therapy can help people with age-related macular degeneration (AMD), diabetic retinopathy (DR), or glaucoma better manage their medications. Participants share their deidentified data to see if therapy improves outcomes.
Worcester, MassachusettsAges 50–100 - NCT06583395Enrolling by invitation
Meditation retreat study with fitness tracker
This trial studies people attending a 7-day meditation retreat to see how meditation affects well-being. You will wear a fitness tracker and answer surveys.
Palm Desert, CaliforniaAges 21 years+ - NCT06557460RecruitingPhase 2
Cell implant for advanced dry age-related macular degeneration
This trial tests a patch of retinal cells implanted under the retina to see if it can slow or stop vision loss from advanced dry AMD (geographic atrophy). It may help people whose central vision is already affected.
Huntington Beach, CaliforniaAges 55–90 - NCT06541704RecruitingPhase 3
Study of pozelimab with cemdisiran for geographic atrophy
This trial tests a combination of two study drugs (pozelimab and cemdisiran) given as a shot under the skin to slow the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes blind spots in central vision.
Chandler, ArizonaAges 50–85 - NCT06489873Recruiting
Lutein, Zeaxanthin, and Fish Oil for Macular Health
This study tests whether taking daily supplements of lutein, zeaxanthin, and fish oil can improve the protective pigment in your eyes. It may help people with low macular pigment and good vision who are not already taking high doses of these nutrients.
College Station, TexasAges 18–45 - NCT06467344RecruitingPhase 1/Phase 2
Testing ACDN-01 for ABCA4 Stargardt eye disease
This trial tests an experimental medicine called ACDN-01 for people with Stargardt retinopathy caused by ABCA4 gene mutations. The goal is to see if it can slow or stop vision loss in an eye with already damaged central vision.
San Francisco, CaliforniaAges 12 years+
Hear when a new Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for macular degeneration?
- Yes. Clin2 currently lists 164 recruiting macular degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a macular degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a macular degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Age-Related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- Neovascular Age-Related Macular Degeneration (nAMD)
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.